Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland

References

• Hajouli S, Ludhwani D. Heart failure and ejection fraction. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356. doi: 10.1002/ejhf.1858.
   PubMed Web of Science ®Google Scholar
• van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18(3):242–252. doi: 10.1002/ejhf.483.
   PubMed Web of Science ®Google Scholar
• Störk S, Handrock R, Jacob J, et al. Epidemiology of heart failure in Germany: a retrospective database study. Clin Res Cardiol. 2017;106(11):913–922. doi: 10.1007/s00392-017-1137-7.
   PubMed Web of Science ®Google Scholar
• Delgado E, Jódar E, Mezquita-Raya P, et al. Benefits of SGLT2i for the treatment of heart failure irrespective of diabetes diagnosis: a state-of-the-art review. Diabetes Ther. 2022;13(Suppl 1):19–34. doi: 10.1007/s13300-022-01278-0.
   PubMed Web of Science ®Google Scholar
• De Couto G, Ouzounian M, Liu PP. Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol. 2010;7(6):334–344. doi: 10.1038/nrcardio.2010.51.
   PubMed Web of Science ®Google Scholar
• Palazzuoli A, Gallotta M, Quatrini I, et al. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411–418. doi: 10.2147/vhrm.s5789.
   PubMedGoogle Scholar
• Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350(mar04 22):h910. doi: 10.1136/bmj.h910.
   PubMedGoogle Scholar
• Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62(15):1365–1372. doi: 10.1016/j.jacc.2013.05.069.
   PubMed Web of Science ®Google Scholar
• Huelsmann M, Neuhold S, Strunk G, et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J. 2008;29(18):2259–2264. Epub 2008 Jul 23. PMID: 18650200. doi: 10.1093/eurheartj/ehn334.
   PubMed Web of Science ®Google Scholar
• Neuhold S, Resl M, Huelsmann M, et al. Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus. Eur J Clin Invest. 2011;41(12):1292–1298. doi: 10.1111/j.1365-2362.2011.02539.x.
   PubMed Web of Science ®Google Scholar
• Clodi M, Resl M, Neuhold S, et al. A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. Eur J Prev Cardiol. 2012;19(5):944–951. doi: 10.1177/1741826711420015.
   PubMed Web of Science ®Google Scholar
• Gaede P, Hildebrandt P, Hess G, et al. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia. 2005;48(1):156–163. doi: 10.1007/s00125-004-1607-0.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. Erratum in: Eur Heart J. 2021. doi: 10.1093/eurheartj/ehab368.
   PubMed Web of Science ®Google Scholar
• van Riet EE, Hoes AW, Limburg A, et al. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014;16(7):772–777. doi: 10.1002/ejhf.110.
   PubMed Web of Science ®Google Scholar
• van Giessen A, Boonman-de Winter LJ, Rutten FH, et al. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15(1):48. doi: 10.1186/s12933-016-0363-z.
   PubMedGoogle Scholar
• Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. Efficiently screening heart failure in patients with type 2 diabetes. Eur J Heart Fail. 2015;17(2):187–195. doi: 10.1002/ejhf.216.
   PubMed Web of Science ®Google Scholar
• Johansson I, Dahlström U, Edner M, et al. Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res. 2018;15(6):494–503. doi: 10.1177/1479164118794619.
   PubMed Web of Science ®Google Scholar
• Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154–2162. doi: 10.1007/s00125-012-2579-0.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the. Value Health. 2012;15(6):796–803. doi: 10.1016/j.jval.2012.06.012.
   PubMed Web of Science ®Google Scholar
• Walter E, Zehetmayr S. [Guidelines for health-economic evaluations in Austria]. Wien Med Wochenschr. 2006;156(23-24):628–632. doi: 10.1007/s10354-006-0360-z.
   PubMedGoogle Scholar
• King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4(5):392–402. doi: 10.1016/j.jchf.2016.02.007.
   PubMed Web of Science ®Google Scholar
• Ford E, Adams J, Graves N. Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open. 2012;2(5):e001094. doi: 10.1136/bmjopen-2012-001094.
   PubMed Web of Science ®Google Scholar
• Yao G, Freemantle N, Flather M, et al. Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. Pharmacoeconomics. 2008;26(10):879–889. doi: 10.2165/00019053-200826100-00007.
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225. doi: 10.1093/eurheartj/ehi115.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303.
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038.
   PubMed Web of Science ®Google Scholar
• Shafie AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev. 2018;23(1):131–145. doi: 10.1007/s10741-017-9661-0.
   PubMed Web of Science ®Google Scholar
• Biermann J, Neumann T, Angermann CE, et al. Resource use and costs in systolic heart failure according to disease severity: a pooled analysis from the german competence network heart failure. J Public Health. 2012;20(1):23–30. doi: 10.1007/s10389-011-0452-0.
   Google Scholar
• Delgado JF, Oliva J, Llano M, et al. Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain. Rev Esp Cardiol (Engl Ed). 2014;67(8):643–650. doi: 10.1016/j.rec.2013.12.014.
   PubMed Web of Science ®Google Scholar
• Czech M, Opolski G, Zdrojewski T, et al. The costs of heart failure in Poland from the public payer’s perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol. 2013;71(3):224–232. doi: 10.5603/KP.2013.0032.
   PubMed Web of Science ®Google Scholar
• Parissis J, Athanasakis K, Farmakis D, et al. Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. Int J Cardiol. 2015;180:46–49. doi: 10.1016/j.ijcard.2014.11.123.
   PubMed Web of Science ®Google Scholar
• Moertl D, Steiner S, Coyle D, et al. Cost-utility analysis of nt-probnp-guided multidisciplinary care in chronic heart failure. Int J Technol Assess Health Care. 2013;29(1):3–11. doi: 10.1017/S0266462312000712.
   PubMed Web of Science ®Google Scholar
• Adlbrecht C, Huelsmann M, Berger R, et al. Cost analysis and cost-effectiveness of nt-proBNP-guided heart failure specialist care in addition to home-based nurse care. Eur J Clin Invest. 2011;41(3):315–322. doi: 10.1111/j.1365-2362.2010.02412.x.
   PubMed Web of Science ®Google Scholar
• Shepard DS. Cost-effectiveness in health and medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996. J Ment Health Policy Econ. 1999;2:91–92. doi: 10.1002/(SICI)1099-176X(199906)2:2<91::AID-MHP46>3.0.CO;2-I.
   Google Scholar
• Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005;26(24):2681–2688. doi: 10.1093/eurheartj/ehi662.
   PubMed Web of Science ®Google Scholar
• Bundesministerium für Soziales, Gesundheit, Pflege und Konsumentenschutz. Überregionale Auswertung der Dokumentation in landesgesundheitsfondsfinanzierten Krankenanstalten 2021, Wien November 2022.
   Google Scholar
• Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935. doi: 10.1016/j.jval.2016.02.017.
   PubMed Web of Science ®Google Scholar
• ICER Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017-2019, USA; 2017. Available from: https://icer-review.org/wp-content/uploads/2017/06/ICER-value-assessment-framework-update-FINAL-062217.pdf.
   Google Scholar
• Laramée P, Wonderling D, Swain S, et al. Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failure. Heart. 2013;99(4):267–271. doi: 10.1136/heartjnl-2012-302692.
   PubMed Web of Science ®Google Scholar
• Mohiuddin S, Reeves B, Pufulete M, et al. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ Open. 2016;6(12):e014010. doi: 10.1136/bmjopen-2016-014010.
   PubMed Web of Science ®Google Scholar
• Siebert U, Milev S, Zou D, et al. Economic evaluation of an N-terminal Pro B-type natriuretic peptide-supported diagnostic strategy among dyspneic patients suspected of acute heart failure in the emergency department. Am J Cardiol. 2021;147:61–69. doi: 10.1016/j.amjcard.2021.01.036.
   PubMed Web of Science ®Google Scholar
• Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005;7(4):537–541. doi: 10.1016/j.ejheart.2005.01.022.
   PubMed Web of Science ®Google Scholar
• Verfahrensordnung zur Herausgabe des Erstattungskodex nach § 351g ASVG – VO-EKO, amtlich verlautbart am 17.6.2004, Nr. 47/2004; zuletzt geändert durch die amtliche Verlautbarung Nr. 40/2020. Available from: https://www.ris.bka.gv.at/Dokumente/Avsv/AVSV_2004_0047/AVSV_2004_0047.pdfsig
   Google Scholar
• Schweizer eidgenossenschaft bundesamt für gesundheit BAG. Operationalisierung der Kriterien “Wirksamkeit, Zweckmässigkeit und Wirtschaftlichkeit” nach Artikel 32 des Bundesgesetzes über die Krankenversicherung (KVG), Version Stand 31.03.2022. Available from: file://Users/ew/Downloads/Operationalisierung%20der%20WZW-Kriterien%20vom%2031.03.2022,%20g%C3%Bcltig%20ab%2001.09.2022%20(1).pdf
   Google Scholar
• Bundesministerium für Gesundheit. Arbeitsunfähigkeit: fälle und Tage nach Diagnosen 2019. Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Statistiken/GKV/Geschaeftsergebnisse/AU_nach_Diagnosen_2019.pdf
   Google Scholar
• Schweizer Eidgenossenschaft Bundesamt für Statistik. Erwerbsquote nach Geschlecht Nationalität, Altersgruppe, Familientyp. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/querschnittsthemen/wohlfahrtsmessung/indikatoren/erwerbsquote.assetdetail.25085638.html
   Google Scholar
• Statistik Austria. Erwerbstätigkeit. Available from: https://www.statistik.at/statistiken/bevoelkerung-und-soziales/gender-statistiken/erwerbstaetigkeit
   Google Scholar
• Schweizer Eidgenossenschaft Bundesamt für Statistik. Schweizerische Lohnstrukturerhebung. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/arbeit-erwerb/erhebungen/lse.html
   Google Scholar
• Statistik Austria. Jährliche Personeneinkommen. Available from: https://www.statistik.at/statistiken/bevoelkerung-und-soziales/einkommen-und-soziale-lage/jaehrliche-personeneinkommen
   Google Scholar
• Beaudet A, Clegg J, Thuresson PO, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462–470. doi: 10.1016/j.jval.2014.03.003.
   PubMed Web of Science ®Google Scholar